Teixeira Maria Cristina Dias, Ribeiro Maria de Fátima Gomes de Sá, Gayotto Luis Carlos da Costa, Chamone Dalton de Alencar Fischer, Strauss Edna
School of Medicine, University of São Paulo (LIM-14), São Paulo, Brazil.
Transfusion. 2006 Feb;46(2):278-83. doi: 10.1111/j.1537-2995.2006.00712.x.
Health-related quality of life (HRQOL) encompasses many different aspects of health perceived by the individual, and its alterations in patients with hepatitis C virus (HCV) have been recently reported. The objective was to study a population of volunteer blood donors at different stages of HCV liver disease.
The Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36), a generic tool, was used to evaluated HRQOL. The SF-36 scores of HCV patients were compared with those of matched healthy blood donors and at the sixth month in those who were submitted to antiviral treatment. Sex, drug use, and alcohol consumption were also evaluated. A total of 120 HCV chronic carriers were divided into three groups: 1) patients with no indication for liver biopsy (n = 37); 2) patients submitted to liver biopsy with mild liver disease (n = 40); and 3) patients with moderate to severe liver disease submitted to interferon plus ribavirin treatment (n = 43).
HCV patients had significantly lower SF-36 scores when compared with matched healthy blood donors. There was no correlation between SF-36 scores and history of intravenous and/or inhaled drug use or alcohol consumption. Women had lower SF-36 scores than men in six domains. At the sixth month of treatment, patients who continued to be positive for the presence of HCV RNA (nonresponders) had lower quality of life than those who became HCV RNA-negative.
Healthy blood donors with HCV showed significantly reduced HRQOL that was more marked in women. The presence of the virus is one of the possible explanations for the reduced HRQOL.
健康相关生活质量（HRQOL）涵盖个体所感知的健康的许多不同方面，最近有报道称丙型肝炎病毒（HCV）患者的HRQOL发生了改变。目的是研究处于HCV肝病不同阶段的志愿献血者群体。
使用通用工具医学结局研究36项简短健康调查（SF - 36）来评估HRQOL。将HCV患者的SF - 36评分与匹配的健康献血者的评分进行比较，并在接受抗病毒治疗的患者中在第六个月时进行比较。还评估了性别、药物使用和饮酒情况。总共120名HCV慢性携带者被分为三组：1）无肝活检指征的患者（n = 37）；2）接受轻度肝病肝活检的患者（n = 40）；3）接受干扰素加利巴韦林治疗的中度至重度肝病患者（n = 43）。
与匹配的健康献血者相比，HCV患者的SF - 36评分显著更低。SF - 36评分与静脉内和/或吸入性药物使用史或饮酒情况之间无相关性。在六个领域中，女性的SF - 36评分低于男性。在治疗的第六个月，HCV RNA仍呈阳性的患者（无应答者）的生活质量低于HCV RNA转为阴性的患者。
HCV阳性的健康献血者的HRQOL显著降低，在女性中更为明显。病毒的存在是HRQOL降低的可能原因之一。
